MoldCo Secures $8M to Expand Telehealth Platform for Environmental Toxin Treatment

MoldCo, a specialized telehealth platform focused on diagnosing and treating mold and environmental toxin exposure, has secured $8 million in seed funding co-led by Cantos and Collaborative Fund. This investment brings the company's total funding to $11 million and will support the expansion of its virtual clinic operations and mission to democratize access to expert-led environmental toxin care.

The funding addresses a substantial healthcare gap affecting millions of Americans. According to available data, more than 50 percent of U.S. households show signs of mold, water damage, or dampness, yet most physicians do not routinely screen for or treat mold-related illnesses. This disconnect leaves patients navigating years of uncertainty, cycling through specialists and accumulating misdiagnoses while experiencing debilitating symptoms.

Mold toxicity can trigger serious long-term health consequences, including Chronic Inflammatory Response Syndrome (CIRS), which healthcare providers frequently misdiagnose as chronic fatigue, fibromyalgia, or anxiety disorders. The complexity of these conditions, combined with limited physician awareness, creates a challenging landscape for patients seeking appropriate care.

MoldCo's telehealth platform offers a streamlined alternative that provides patients with immediate access to evidence-based treatments at significantly reduced costs. The company's treatment protocols average $150 to $300 per month, representing substantial savings compared to traditional approaches that can cost tens of thousands of dollars without guaranteed outcomes.

The platform's founder and CEO, Ariana Thacker, developed the concept from personal experience battling severe mold illness within conventional medical systems. "It revealed a critical gap: individuals are suffering because the specialized knowledge needed to diagnose and treat these conditions is widely unavailable. MoldCo was born from that experience. By combining specialized clinical expertise with telehealth accessibility, we're making evidence-based care available to everyone who needs it as quickly as possible, at a fraction of the current cost," said Thacker.

MoldCo simplifies the treatment process through three core steps: symptom clarity assessment, virtual care access, and home-delivered treatments. The platform connects patients with certified specialists, provides advanced laboratory testing, delivers evidence-based treatment protocols, and offers continuous support through dedicated care navigators.

The new funding will enable MoldCo to expand its network of specialized clinicians across the United States, advance proprietary care technology development, and invest in clinical research collaborations. Currently offering advanced lab testing in 46 states and providing care in select markets, the company plans nationwide availability by 2026, with the goal of standardizing mold detoxification as routine healthcare comparable to annual physicals or dental examinations.

Click here for the original news story.